Mitochondrial ROS‑Src Axis Drives Early Tight Junction Loss in Aging Gut, Preceding Inflammaging
Hypothesis
Age‑related increase in mitochondrial reactive oxygen species (ROS) within colonic epithelial cells activates Src family kinases, leading to tyrosine phosphorylation of ZO‑1 and weakening of the ZO‑1/occludin complex. This redox‑dependent junctional destabilization occurs before measurable rises in systemic inflammatory cytokines, positioning mitochondrial ROS as an upstream trigger of barrier failure that initiates inflammaging rather than resulting from it.
Mechanistic Basis
Mitochondrial ROS can oxidize specific cysteine residues in Src, promoting its autophosphorylation and activation (see redox regulation of Src)[2]. Active Src phosphorylates ZO‑1 on tyrosine residues, disrupting its PDZ‑mediated binding to occludin and facilitating ZO‑1 redistribution to the cytosol[2]. Loss of this scaffold compromises the actin‑tight junction linkage, increasing paracellular permeability to bacterial products such as LPS. LPS‑TLR4 signaling then fuels NF‑κB‑driven IL‑6 and TNF‑α production, completing the inflammaging loop[4]. Importantly, this sequence places ROS‑Src activation upstream of cytokine elevation, offering a testable causal direction.
Predictions and Experimental Design
- In human colonic biopsies from individuals aged 40‑80, mitochondrial ROS markers (e.g., mitochondrial 8‑hydroxy‑2′‑deoxyguanosine, SOD2 expression) will positively correlate with Src‑pY416 levels and negatively correlate with ZO‑1/occludin junctional abundance, independent of current plasma IL‑6 or TNF‑α concentrations.
- Longitudinal sampling (baseline, 2‑year, 5‑year follow‑up) will show that increases in mitochondrial ROS‑Src signaling predict subsequent declines in ZO‑1/occludin at the next visit, whereas rises in IL‑6/TNF‑α will follow the junctional loss.
- Interventions that suppress mitochondrial ROS (e.g., mito‑targeted antioxidants like MitoQ) or inhibit Src (e.g., low‑dose dasatinib) in ex vivo cultured aging colonic biopsies will preserve ZO‑1/occludin localization and reduce LPS‑induced cytokine release compared with untreated controls.
To test these predictions, we propose a cohort study with endoscopic mucosal biopsies from the sigmoid colon at each time point. Assays include: mitochondrial ROS detection via MitoSOX flow cytometry, Src activation by western blot for pY416‑Src, tight junction protein quantification by immunofluorescence and immunoblotting, and plasma cytokine ELISA. Statistical analysis will use mixed‑effects models to assess temporal precedence.
Potential Implications
If confirmed, this hypothesis shifts the therapeutic focus from anti‑cytokine strategies to early redox‑Src modulation for preserving gut barrier integrity during aging. It also provides a mechanistic bridge between mitochondrial dysfunction—a hallmark of aging—and inflammaging, offering a novel target for interventions aimed at extending healthspan.